San Antonio, Texas USA (UroToday.com) Andrew K. Kadar, University of California San Diego, further discussed germline susceptibility for bladder cancer diagnosis and treatment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Bladder cancer has up to 30% heritability, however, there is a lack of research discerning germline mutations and bladder cancer. Out of approximately 100 bladder cancer patients and 54 DNA-repair genes, 15% had pathogenic mutations in DNA-repair genes in bladder cancer. Interestingly, T1 patients had more mutations than Ta patients. Among the T1 patients, 6 out of 7 carriers had greater recurrence rates. Inherited cancer panels are being developed combining high penetrance genes with single nucleotide polymorphisms. For the health individual, evaluating the risk of bladder cancer may be further elucidated with prediction of response and targeted therapies for those diagnosed with bladder cancer.
Presented by: Andrew K. Kadar, University of California San Diego
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA